Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of ustekinumab in pediatric participants with Crohn's disease, ulcerative colitis, or juvenile psoriatic arthritis
MOH_2024-05-23_013279Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of ustekinumab in Crohn's disease, autoimmune colitis and juvenile psoriatic arthritis (JPsA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Long-term safety of ustekinumab. Started May 2024; status: active, not recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's diseaseautoimmune colitisjuvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on MOH_2024-05-23_013279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-23_013279.